KymaThera plans to dose the first patients in its Phase I trial on K-1728 in Q4 2026.
The arrangement will see Cognizant combine its life sciences knowledge with technical services to aid Gilead's processes.
Under the terms of the agreement, Rocket drew an initial $35m upon closing.
Shionogi's acquisition of IntraBio would expand its rare disease portfolio following the recent acquisition of ALS drug, Radicava.
Lilly is continuing to bet on the molecular gate approach, which Gate says could create therapies targeting hard-to-drug proteins.
Alector’s approach combines an engineered GCase with the biotech’s blood-brain barrier delivery platform.
